Indian generic drug maker BDR Pharma's plans could draw new battles lines over intellectual property rights. After seeking a compulsory license for leukemia drug Sprycel, BDR Pharma is setting its sight on more patent-protected anti-cancer drugs, reports CNBC-TV18's Archana Shukla.
first published: Mar 22, 2013 06:25 pm
A collection of the most-viewed Moneycontrol videos.
Live: Can Nifty reclaim record levels as investors await FOMC decision this week? | Opening Bell
Why This Tenant Says Bandra Is Better Than California | The Tenant
Nifty Clocks Triple-Digit Gains After RBI Rate Cut But Logs Losses For The Week| Closing Bell Live
LIVE: RBI Governor Sanjay Malhotra Delivers Key Monetary Policy Statement | Interest Rates & Outlook
